Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the GI tract and is primarily driven by activating mutations in receptor tyrosine kinases.1,2 KIT and PDGFRA mutations are the drivers of ~85% of GIST and keep the kinase in the active state, causing uncontrolled cell proliferation and/or cell survival.2-4

In localized disease, the primary treatment includes surgery (resectable GIST).5,6  In advanced or metastatic disease, tyrosine kinase inhibitors are recommended.6

Explore Ripretinib Data in GIST

Disclosures:

This information is being provided to you in the context of scientific exchange and is not intended for promotion. The scientific publications contain information about uses of ripretinib outside the FDA-approved labeling. Ripretinib has not been approved by the FDA in these settings and the safety and effectiveness in these settings have not been established. Providing this information should not be construed as a recommendation for unapproved uses.

Ripretinib is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. There are no contraindications for ripretinib. Warnings and Precautions associated with ripretinib include: Palmar-Plantar Erythrodysesthesia Syndrome, New Primary Cutaneous Malignancies, Hypertension, Cardiac Dysfunction, Risk of Impaired Wound Healing, Photosensitivity, and Embryo-Fetal Toxicity. Please refer to the accompanying Prescribing Information, including safety information, for complete details.

  • Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.

     

    • Heinrich MC, et al. Nat Med. 2024;30:498-506. Read full article.
    • Important information for readers:
      • This article contains information not included on the FDA-approved labeling for QINLOCK (ripretinib) 150 mg.
      • INTRIGUE was an open-label, phase 3 study in adult patients with advanced GIST who had disease progression on or intolerance to imatinib and who were randomized to ripretinib 150 mg once daily or sunitinib 50 mg once daily (4 weeks on/2 weeks off). In this exploratory analysis, the researchers hypothesized that given the differential activity of tyrosine kinase inhibitors depending on the location of the KIT mutations, further investigation by mutational subgroup using ctDNA could provide more insight into the efficacy of ripretinib and sunitinib as second line therapies.
    • Disclosures:
      • This clinical study was supported by Deciphera and the following authors are or were employees of the company: Ying Su, Julie Meade, Tao Wang, William Reichmann, Kam Sprott, Haroun Achour, Matthew L. Sherman, and Rodrigo Ruiz-Soto.
      • Additional authors who have recieved compensation from Deciphera include: Michael, C. Heinrich (Consulting/Advisory Role), Robin L. Jones (Consulting/Advisory Role), Suzanne George (Consulting/Advisory Role, Institutional Research Funding), Hans Gelderblom (Institutional Research Funding), Patrick Schöffski (Consulting/Advisory Role), Margaret von Mehren (Consulting/Advisory Role, Institutional Research Funding), John R. Zalcberg (Honoraria, Consulting/Advisory Role, Travel/Accommodation Support), Albiruni Abdul Razak (Research Funding), Johnathan Trent (Consulting/Advisory Role), Steven Attia (Institutional Research Funding), Alex le Cesne (Honoraria), Brittany L. Siontis (Consulting/Advisory Role, Institutional Research Funding), Neeltje Steeghs (Institutional Research Funding), Mihaela Druta (Consulting/Advisory Role, Speaker Bureau Participation), César Serrano (Consulting/Advisory Role, Honoraria), Neeta Somaiah (Consulting/Advisory Role, Research Funding), Ping Chi (Consulting/Advisory Role, Research Funding), Jean Yves-Blay (Honoraria, Consulting/Advisory Role, Institutional Research Funding), Sebastian Bauer (Honoraria, Consulting/Advisory Role).
      • See authors' full disclosures of potential conflicts of interest contained within the publication.

  • Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor
    • Zalcberg JR, et al. Oncologist. 2021;26(11):e2053-e2060. Read full article.
    • George S, et al. Eur J Cancer. 2021;155:236-244. Read full article.
    • Important information for readers:
      • These articles contain information not included on the FDA-approved labeling for QINLOCK (ripretinib) 150 mg.
      • Intrapatient dose escalation (IPDE) of ripretinib as an alternative therapeutic option after disease progression was explored in a Phase I study and the Phase III INVICTUS study.
    • Disclosures:
      • These clinical studies were supported by Deciphera Pharmaceuticals, LLC and the following authors are or were employees of the company: Julie Meade, Julia Jennings, Ying Su, Vienna Reichert, Kelvin Shi, Matthew L. Sherman, and Rodrigo Ruiz-Soto.
      • The following authors report financial relationships with Deciphera Pharmaceuticals, LLC: John R. Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, César Serrano, Hans Gelderblom, Robin L. Jones, Steen Attia, Kristen Ganjoo, Johnathan Trent, Albiruni Abdul Razak, Michael S. Gordon, Gina D'Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Margaret von Mehren, Filip Janku, Jean-Yves Blay. 

  • Updated overall survival and long-term safety with ripretinib versus sunitinib in patients with GI stromal tumor
    • Heinrich MC, et al. J Clin Oncol. 2025;43(20):2239-2244. Read full article.
    • Important information for readers:
      • This article contains information not included on the FDA-approved labeling for QINLOCK (ripretinib) 150 mg.
      • INTRIGUE was an open-label, phase 3 study in adult patients with advanced GIST who had disease progression on or intolerance to imatinib and who were randomized to ripretinib 150 mg once daily or sunitinib 50 mg once daily (4 weeks on/2 weeks off). This study reports the final planned analysis of overall survival and long-term safety.
    • Disclosures:
      • This clinical study was supported by Deciphera Pharmaceuticals, LLC and the following authors are or were employees of the company: Paulina Cox, Erika Davis, Matthew L. Sherman, and Rodrigo Ruiz-Soto.
      • The following authors report financial relationships with Deciphera Pharmaceuticals, LLC: Michael C. Heinrich, Jean Yves-Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John R. Zalcberg, Robin L. Jones, Albiruni Abdul Razak, Johnathan Trent, Steven Attia, Axel Le Cesne, Kjetil Boye, Brittany L. Siontis, Sebastian Bauer.

References

1) Corless CL, et al. Nat Rev Cancer. 2011;11(12):865-878. 
2) Li K, et al. Oncotarget. 2017;8(36):60589-60604. 
3) Antonescu CR, et al. Clin Cancer Res. 2005;11(11):4182–4190. 
4) Zhao X, Yue C. J Gastrointest Oncol. 2012;3(3):189–208. 
5) Gold JS, et al. Ann Surg. 2006;244(2):176-184. 
6) Huang WK, et al. Curr Treat Options Oncol. 2022;23(9):1303-1319.